Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Long-term outcomes of ex-vivo stem cell allograft transplantation for ocular surface failure

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Cornea: Surgical II

Session Date/Time: Tuesday 08/09/2015 | 14:00-16:00

Paper Time: 15:48

Venue: Room 11

First Author: : E.Sykakis UK

Co Author(s): :    M. Modell   A. Barua   S. Hamada   D. Lake           

Abstract Details

Purpose:

Short-term results have shown the procedure to be effective in restoring cornea phenotype epithelium. Long-term results, however, can vary considerably with some studies reporting less successful outcomes. The purpose of this study was to investigate how sucessful the procedure can be in the long term.

Setting:

Corneo-Plastic Unit, Queen Victoria Hospital, East Grinstead, UK

Methods:

A case series of patients that underwent EXVSCALT at a tertiary cornea centre was conducted. Clinical data and various outcome parameters were collected from patient records.

Results:

41 patients with a median age of 44 years (range, 3-71) received an ex-vivo stem cell allograft. Mean follow-up time was 72.6±48.38 months (1-175). The number of eyes receiving a transplant was 51 (48 non-related cadaveric, 3 living-relative). Survival rate of the 48 stem cell transplants was 84.09% (37 out of 44 eyes) at one year, 71.43% (30/42) at 2 years, 41.67% (15/36) at 5 years and 10.71% (3/28) at 10 years. Best-corrected logMAR visual acuity pre-operative was 1.6±1.81 (0.18-2.8) improving to 1.45±0.72 (0.2-2.8) at last follow-up appointment.

Conclusions:

EXVSCALT provides medium-term ocular surface rehabilitation in selected LSCD aetiology groups while in high risk groups success rate is less. EXVSCALT provides the possibility of repeat procedure.

Financial Interest:

NONE

Back to previous